Abstract
The incidence of breast cancer is rising throughout the world. Breast cancer is slowly becoming more prevalent in countries which previously had low rates of cancer as well as becoming a leading cause of cancer death in some countries. Fortunately, a large number of these tumors are estrogen receptor (ER) positive and respond to anti-hormonal adjuvant therapy which until recently has been 5 years of tamoxifen treatment. Unfortunately, a significant number of patients develop recurrent cancers and the recurrent tumors are resistant to tamoxifen treatment. In addition, because of tamoxifen’s selective estrogenic actions, there have been reports of venous thrombosis, endometrial cancer, and strokes in patients receiving tamoxifen therapy. Thus, there are other novel therapies such as aromatase inhibitors that block estrogen production in postmenopausal women or fulvestrant that destroys the estrogen receptor. This paper will summarize the therapeutic options for anti-hormonal therapy, the role of anti-hormonal agents in advanced breast cancer, and adjuvant therapy and the current status of chemoprevention with selective ER modulators.
Similar content being viewed by others
References
McPherson K, Steel CM, Dixon JM: (ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics).BMJ 321 (7261):624–628, 2000.
Breast Cancer Facts and Figures.American Cancer Society. 2005–2006.
Kols A: (Breast Cancer; increasing incidence, limited options).Outlook 19:1–8, 2002.
Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T: (Cancer incidence and incidence rates in Japan in 2000: estimates based on data from 11 population-based cancer registries).Jpn J Clin Oncol 36:668–675, 2006.
Japanese Cancer Society:http://www.jcancer.jp/en/screening.html. 2005.
Vital Statistics of Japan: Statistics and Information Department. Minister’s Secretariat, Ministry of Health, Labour and Welfare. 2001.
Japanese Cancer Society: http://www.ncc.go.jp/en/statistics/2005/index.html. 2005.
Mettlin C: Global breast cancer mortality statistics. CA.Cancer J Clin 49:138–144, 1999.
Tung HT, Tsukuma H, Tanaka H, Kinoshita N, Koyama Y, Ajiki W, Oshima A, Koyama H: (Risk factors for breast cancer in Japan, with special attention to anthropometric measurements and reproductive history).Japanese Journal of Clinical Oncology 29:137–146, 1999.
Li CI, Daling JR, Malone KE: (Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998).J Clin Oncol 21:3–4, 2003.
Anderson WF, Chatterjee N, Ershler WB, Brawley OW: (Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database).Breast Cancer Research and Treatment 76:27–36, 2002.
Nomura Y, Tashiro H, Hamada Y, Shigematsu T: (Relationship between estrogen receptors and risk factors of breast cancer in Japanese pre-and postmenopausal patients).Breast Cancer Res Treat 4:37–43, 1984.
Matsumoto K, Sakamoto G, Nomura Y: (International comparisons concerning breast cancer and steroid receptors).Anticancer Research 6:621–624, 1986.
McGuire WL, Carbone PP, Sears ME, Escher GC: Estrogen receptors in human breast cancer: an overview. In: Estrogen Receptor in Human Breast Cancer. McGuire WL, Carbone PP, Volmer EP eds Raven Press, New York, pp 1–7, 1975.
Nomura Y, Kobayashi S, Takatani O, Sugano H, Matsumoto K, McGuire WL: (Estrogen receptor and endocrine responsiveness in Japanese versus American breast cancer patients).Cancer Res 37:106–110, 1977.
Jensen EV, Jacobson HI: (Basic guides to the mechanism of estrogen action).Recent Progr Hormone Res 18:387–414, 1962.
Jensen EV, Jordan VC: (The estrogen receptor: a model for molecular medicine. The Dorothy P. Landon AACR Prize for Translational Research).Clin Cancer Res 9:1980–1989, 2003.
Russo J, Fernandez SV, Russo PA, Fernbaugh R, Sheriff FS, Lareef HM, Garber J, Russo IH: (17-Beta-estradiol induces transformation and tumorigenesis in human breast epithelial cells).Faseb J 20:1622–1634, 2006.
Cavalieri E, Chakravarti D, Guttenplan J, Hart E, Ingle J, Jankowiak R, Muti P, Rogan E, Russo J, Santen R, Sutter T: (Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention).Biochim Biophys Acta 1766:63–78, 2006.
NCI Website: http://cancer.gov.cancertopics/understandingcancer.
EBCTCG: (Tamoxifen for early breast cancer: an overview of the randomised trials).Lancet 354:1451–1467, 1998.
Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: (Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study).J Natl Cancer Inst 90:1371–1388, 1998.
Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A: (A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group).Cancer 79:730–739, 1997.
de Ziegler D, Mattenberger C, Luyet C, Romoscanu I, Irion NF, Bianchi-Demicheli F: (Clinical use of aromatase inhibitors (AI) in premenopausal women).J Steroid Biochem Mol Biol 95(1-5):121–127, 2005.
Johnston S: (Fulvestrant and the sequential endocrine cascade for advanced breast cancer).British J Cancer 90 Suppl 1:s15–18, 2004.
Jonat W: (Goserelin (Zoladex)-its role in early breast cancer in pre-and perimenopausal women).Br J Cancer 85 Suppl 2:1–5, 2001.
Jordan VC: (Tamoxifen: a most unlikely pioneering medicine).Nature Reviews Drug Discovery 2:205–213, 2003.
Furr BJ, Jordan VC: (The pharmacology and clinical uses of tamoxifen).Pharmacol Ther 25:127–205, 1984.
Cole MP, Jones CT, Todd ID: (A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI 46474).Br J Cancer 25:270–275, 1971.
Jordan VC, Allen KE: (Evaluation of the antitumour activity of the non-steroidal antioestrogen monohy-droxytamoxifen in the DMBA-induced rat mammary carcinoma model).Eur J Cancer 16:239–251, 1980.
Jordan VC: Use of the DMBA-induced rat mammary carcinoma system for the evaluation of tamoxifen as a potential adjuvant therapy. Reviews on Endocrine-Related Cancer (October Supplement):49–55, 1978.
EBCTCG: (Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials).Lancet 365:1687–1717, 2005.
Osborne CK: (Tamoxifen in the treatment of breast cancer).N Engl J Med 339:1609–1618, 1998.
Howell A, Dodwell DJ, Anderson H, Redford J: (Response after withdrawal of tamoxifen and progestogens in advanced breast cancer).Ann Oncol 3:611–617, 1992.
Gottardis MM, Jordan VC: (Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration).Cancer Res 48:5183–8187, 1988.
Jordan VC: (Selective estrogen receptor modulation: concept and consequences in cancer).Cancer Cell 5:207–213, 2004.
Miller WR, Dixon JM: (Antiaromatase agents: preclinical data and neoadjuvant therapy).Clin Breast Cancer Suppl 1:S9–14, 2000.
Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann W, Wolter JM, Steinberg M, Webster A, Lee D: (Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group).Cancer 83:1142–1152, 1998.
Howell A, Robertson JFR, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergot I, Erikstein B, Webster A, Morris C: (Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment).J Clin Oncol 20:3396–3403, 2002.
Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A: (Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial).J Clin Oncol 20:3386–3395, 2002.
Boccardo F, Rubagotti A, Puntoni M, Guglielmini P, Amoroso D, Fini A, Paladini G, Mesiti M, Romeo D, Rinaldini M, Scali S, Porpiglia M, Benedetto C, Restuccia N, Buzzi F, Franchi R, Massidda B, Distante V, Amadori D, Sismondi P: (Switching to anastrozole versus continued tamoxifen treatment for early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole Trial).J Clin Oncol 23:5138–5147, 2005.
Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM: (A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer).N Engl J Med 350:1081–1092, 2004.
Goss PE, Ingle JN, Marino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL: (A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for earlystage breast cancer).N Engl J Med 349:1–10, 2003.
ATAC Trialists’ Group: (Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial).Lancet 359:2134–3139, 2002.
Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS, Group AT: (Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer).Lancet 365:60–62, 2005.
Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardly A, Price KN, Goldhirsch A, BIG (Breast International Group), Group I-C: (A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer).N Engl J Med 353:2747–2757, 2005.
Jordan VC: (Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinoma).Eur J Cancer 12:419–424, 1976.
Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N: (Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study).J Natl Cancer Inst 97:1652–1662, 2005.
Jordan VC: (Optimising endocrine approaches for the chemoprevention of breast cancer. Beyond the Study of Tamoxifen and Raloxifene (STAR) Trial).European Journal of Cancer 42:2909–2913, 2006.
Jordan VC, Phelps E, Lindgren JU: (Effects of anti-estrogens on bone in castrated and intact female rats).Breast Cancer Res Treat 10:31–35, 1987.
Gottardis MM, Jordan VC: (Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model).Cancer Res 47:4020–4024, 1987.
Jordan VC: (Chemosuppression of breast cancer with tamoxifen: laboratory evidence and future clinical investigations).Cancer Invest 6:589–595, 1988.
Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC: (The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation).JAMA 281:2189–2197, 1999.
Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR: (For the CORE Investigators Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene).J Natl Cancer Inst 96:1751–1761, 2004.
Jordan VC: Chemoprevention of breast cancer with selective oestrogen-receptor modulators. Nature Reviews Cancer (in press) 2007.
Jordan VC: SERMs: meeting the promise of multifunctional medicines. (Commentary). J ournal of the National Cancer Institute (in press) 2007.
Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehren-bacher L, Pajon (jr) ER, Wade I.J.L., Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N: (The Study of Tamoxifen and Raloxifene (STAR): Report of the National Surgical Adjuvant Breast and Bowel Project P-2 Trial).JAMA 295:2727–2741, 2006.
http://www.ibcsg.org/public/general-pages/trialsJopen/IBIS-II/trial-IBISII.html.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Patel, R.R., Sharma, C.G.N. & Jordan, V.C. Optimizing the antihormonal treatment and prevention of breast cancer. Breast Cancer 14, 113–122 (2007). https://doi.org/10.2325/jbcs.966
Published:
Issue Date:
DOI: https://doi.org/10.2325/jbcs.966